Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL11023364 | 0.85 | ADRA2A (0.51) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL28018862 | 0.85 | CYP11B1 (0.56) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL30606777 | 0.84 | POLB (0.52) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL5457794 | 0.84 | POLB (0.55) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL23515364 | 0.82 | CYP11B1 (0.50) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL29625759 | 0.82 | CYP11B1 (0.50) | POLBFYNMKNK1MKNK2CYP11B1 | |
| SCHEMBL31663902 | 0.82 | MKNK1 (0.62) | POLBMKNK1MKNK2CYP11B1CYP11B2 | |
| SCHEMBL8057350 | 0.81 | KDM4E (0.67) | POLBALDH1A1CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL8054297 | 0.81 | KDM4E (0.56) | POLBFYNALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL6754272 | 0.81 | CYP1A2 (0.54) | POLBALDH1A1CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160745-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-25 | — | — | US | disclosed |
| CN-108290838-A | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| US-20180009780-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3030553-B1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| CN-105452233-B | Piperidine and azepane derivatives as prokineticin receptor modulators | 武田药品工业株式会社 | 2017-12-08 | — | — | CN | disclosed |
| US-9790201-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20160185752-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-30 | — | — | US | disclosed |
| EP-3030553-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019103-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
| CN-101801931-B | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | ALMIRALL SA | 2014-05-14 | — | — | CN | disclosed |
| CN-100439337-C | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-1717389-A | Phenyl substituted piperidine compounds for use as PPAR activators | PFIZER PROD INC (US) | 2006-01-04 | — | — | CN | disclosed |
| EP-1037876-A1 | BIPHENYL DERIVATIVES AS PHARMACEUTICALS | Novartis AG (CH) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999023073-A1 | BIPHENYL DERIVATIVES AS PHARMACEUTICALS | NOVARTIS AG (CH) | 1999-05-14 | — | — | WO | disclosed |
| EP-0148826-A1 | FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1985-07-24 | — | — | EP | disclosed |
| WO-1985000289-A1 | FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS | CHEVRON RESEARCH COMPANY (US) | 1985-01-31 | — | — | WO | disclosed |
| US-4407806-A | PRE- AND POSTEMERGENCE HERBICIDES | CHEVRON RESEARCH COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160745-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | GIPR, PROKR1, PROKR2 | POLB 4358/4885FYN 4436/4885MKNK1 1035/4885 |
| US-20160185752-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | GIPR, PROKR1, PROKR2 | POLB 4345/4885FYN 4410/4885MKNK1 1048/4885 |
| US-20180009780-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | GIPR, PROKR1, PROKR2 | POLB 4358/4885FYN 4436/4885MKNK1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.